ViroPharma Inc. (NASDAQ:VPHM) recently announced that its lead drug, Cinryze (intravenous formulation) is now available in the United Kingdom (UK) for the prevention, pre-procedure prevention, and treatment of attacks of hereditary angioedema (HAE) in adolescent and adult patients.
HAE is a rare, debilitating and life-threatening genetic disorder, which causes the larynx, face, abdomen, extremities and urogenital tract to swell.
We note that Cinryze is currently marketed in the US for the prevention … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards